Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2005

View Archived Issues

Neuroprotective antiinflammatory effects of the MLK inhibitor CEP-1347 shown in vitro and in vivo

The potent antitumor candidate XR-5944 displays a unique mechanism of action

AGS-PSCA: a candidate for clinical trials in prostate, pancreatic cancers

Transgenomic to provide additional nucleic acid products to Geron

Second phase review in Europe of Johnson & Johnson's acquisition of Guidant

Japan Tobacco and Torii pharma production facilities to merge

Exelixis submits IND for XL-820

Orphan drug designation for doxorubicin Transdrug in primary liver cancer

ThromboView update

Alizyme completes thorough cardiovascular safety trial of renzapride

Japanese approval of biopharmaceutical using GroPep's Cell Culture Products

Enrollment completed in diabetes study of Diamyd in children

Phase IIb study of Hamilton's HL-0812 supported by Series A financing

Myriad presents new data on anticancer drug candidates MPC-2130 and MPC-6827

Recent patents describe therapeutic agents for asthma

New immunomodulatory agents disclosed by General Atomics

Novel agents for urinary incontinence and renal disorders imparted in recent patents

New data on the safety profile of 17-AAG in patients with solid tumors

Discovery and preclinical profile of dual VEGFR-2/FGFR-1 kinase inhibitors

PU-H58, a highly potent and selective Hsp90 inhibitor

Promising results reported for SGN-40 in recurrent multiple myeloma

Preclinical evidence supports the use of CYC-202 in multiple myeloma

Update on lenalidomide in multiple myeloma

MP4 safe in human volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...